Keywords
Last Name
Institution

FRANCOIS-XAVIER CLARET

TitleAssociate Professor
InstitutionMD Anderson
DepartmentSystems Biology
Address6565 MD Anderson Blvd
Houston TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Atsaves V, Zhang R, Ruder D, Pan Y, Leventaki V, Rassidakis GZ, Claret FX. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism. Leukemia. 2015 Nov; 29(11):2162-72. PMID: 25987255.
      View in: PubMed
    2. Wang S, Zhang R, Claret FX, Yang H. Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. Mol Cancer Ther. 2014 Dec; 13(12):3163-74. PMID: 25319395.
      View in: PubMed
    3. Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. Br J Haematol. 2014 Nov; 167(4):514-23. PMID: 25145835.
      View in: PubMed
    4. Vu T, Sliwkowski MX, Claret FX. Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta. 2014 Dec; 1846(2):353-65. PMID: 25065528.
      View in: PubMed
    5. Pan Y, Yang H, Claret FX. Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. Cancer Biol Ther. 2014 Mar 1; 15(3):256-62. PMID: 24495954; PMCID: PMC3974825.
    6. Zhou F, Meng S, Song H, Claret FX. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev. 2013 Nov; 27(6):261-7. PMID: 24054128; PMCID: PMC4133945.
    7. Pan Y, Wang M, Bu X, Zuo Y, Wang S, Wang D, Liu Q, Su B, Xu T, Wang C, Claret FX, Yang H. Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma. BMC Cancer. 2013; 13:323. PMID: 23815987; PMCID: PMC3706359.
    8. Zhou F, Shen Q, Claret FX. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. J Leukoc Biol. 2013 Sep; 94(3):423-9. PMID: 23715741; PMCID: PMC4051257.
    9. Pan Y, Zhou F, Zhang R, Claret FX. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS One. 2013; 8(1):e54565. PMID: 23382914.
      View in: PubMed
    10. Pan Y, Claret FX. Targeting Jab1/CSN5 in nasopharyngeal carcinoma. Cancer Lett. 2012 Dec 30; 326(2):155-60. PMID: 22867945.
      View in: PubMed
    11. Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene. 2013 May 30; 32(22):2756-66. PMID: 22797071; PMCID: PMC3566273.
    12. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012; 2:62. PMID: 22720269.
      View in: PubMed
    13. Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, Claret FX, Yang H. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 2012 Apr 1; 72(7):1890-900. PMID: 22350412; PMCID: PMC3460549.
    14. Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Res. 2012; 2012:659649. PMID: 22121480; PMCID: PMC3206369.
    15. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst. 2011 Sep 21; 103(18):1403-22. PMID: 21813412.
      View in: PubMed
    16. Shackleford TJ, Zhang Q, Tian L, Vu TT, Korapati AL, Baumgartner AM, Le XF, Liao WS, Claret FX. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast Cancer Res. 2011; 13(3):R65. PMID: 21689417; PMCID: PMC3218954.
    17. Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ, Vega F, Medeiros LJ. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia. 2011 May; 25(5):856-67. PMID: 21394100; PMCID: PMC3094765.
    18. Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas. Hum Pathol. 2011 Aug; 42(8):1117-24. PMID: 21315423; PMCID: PMC4089890.
    19. Shackleford TJ, Claret FX. JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div. 2010; 5:26. PMID: 20955608.
      View in: PubMed
    20. Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene. 2010 Nov 18; 29(46):6125-37. PMID: 20802511.
      View in: PubMed
    21. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 1; 16(1):184-94. PMID: 20028751; PMCID: PMC3716580.
    22. Shin S, Asano T, Yao Y, Zhang R, Claret FX, Korc M, Sabapathy K, Menter DG, Abbruzzese JL, Reddy SA. Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism. Mol Cancer Res. 2009 May; 7(5):745-54. PMID: 19435822; PMCID: PMC4854281.
    23. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol. 2007 Aug; 31(2):441-9. PMID: 17611702.
      View in: PubMed
    24. Leventaki V, Drakos E, Medeiros LJ, Lim MS, Elenitoba-Johnson KS, Claret FX, Rassidakis GZ. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood. 2007 Sep 1; 110(5):1621-30. PMID: 17416736.
      View in: PubMed
    25. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, Ho L, Evans DB, Claret FX. Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma. Cancer Res. 2006 Sep 1; 66(17):8581-9. PMID: 16951171; PMCID: PMC1780177.
    26. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006 Jul 1; 66(13):6589-97. PMID: 16818631; PMCID: PMC4839264.
    27. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, Lotan R. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene. 2006 May 4; 25(19):2785-94. PMID: 16407847.
      View in: PubMed
    28. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX, Medeiros LJ. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol. 2005 Oct; 18(10):1365-70. PMID: 15920551; PMCID: PMC1382062.
    29. Zhang Q, Tian L, Mansouri A, Korapati AL, Johnson TJ, Claret FX. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. FEBS Lett. 2005 Jul 18; 579(18):3932-40. PMID: 15996662; PMCID: PMC1366489.
    30. Rassidakis GZ, Feretzaki M, Atwell C, Grammatikakis I, Lin Q, Lai R, Claret FX, Medeiros LJ, Amin HM. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood. 2005 Jan 15; 105(2):827-9. PMID: 15374880.
      View in: PubMed
    31. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004 Mar 5; 279(10):9653-61. PMID: 14670967.
      View in: PubMed
    32. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res. 2003 Nov 15; 9(15):5652-9. PMID: 14654548.
      View in: PubMed
    33. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res. 2003 Jun 1; 63(11):2977-81. PMID: 12782606.
      View in: PubMed
    34. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem. 2003 Jun 27; 278(26):23441-50. PMID: 12700233.
      View in: PubMed
    35. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 2003 May 23; 278(21):19245-56. PMID: 12637505.
      View in: PubMed
    36. Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, McDonnell TJ, Medeiros LJ. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res. 2003 Mar; 9(3):1121-8. PMID: 12631617.
      View in: PubMed
    37. Pyle ME, Korbonits M, Gueorguiev M, Jordan S, Kola B, Morris DG, Meinhardt A, Powell MP, Claret FX, Zhang Q, Metz C, Bucala R, Grossman AB. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol. 2003 Jan; 176(1):103-10. PMID: 12525254.
      View in: PubMed
    38. Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res. 2003; 13(6-10):399-404. PMID: 12725530; PMCID: PMC4089892.
    39. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002 Jun; 87(6):2635-43. PMID: 12050228.
      View in: PubMed
    40. Aytac U, Claret FX, Ho L, Sato K, Ohnuma K, Mills GB, Cabanillas F, Morimoto C, Dang NH. Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res. 2001 Oct 1; 61(19):7204-10. PMID: 11585756.
      View in: PubMed
    41. Deng L, Lin-Lee YC, Claret FX, Kuo MT. 2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem. 2001 Jan 5; 276(1):413-20. PMID: 11020383.
      View in: PubMed
    42. Lee HY, Sueoka N, Hong WK, Mangelsdorf DJ, Claret FX, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity. Mol Cell Biol. 1999 Mar; 19(3):1973-80. PMID: 10022884.
      View in: PubMed
    43. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol. 1999 Jan; 19(1):751-63. PMID: 9858598; PMCID: PMC83932.
    44. Herdegen T, Claret FX, Kallunki T, Martin-Villalba A, Winter C, Hunter T, Karin M. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J Neurosci. 1998 Jul 15; 18(14):5124-35. PMID: 9651196.
      View in: PubMed
    45. Lee HY, Dawson MI, Claret FX, Chen JD, Walsh GL, Hong WK, Kurie JM. Evidence of a retinoid signaling alteration involving the activator protein 1 complex in tumorigenic human bronchial epithelial cells and non-small cell lung cancer cells. Cell Growth Differ. 1997 Mar; 8(3):283-91. PMID: 9056670.
      View in: PubMed
    46. Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 1996 Oct 3; 383(6599):453-7. PMID: 8837781.
      View in: PubMed
    47. Claret FX, Antakly T, Karin M, Saatcioglu F. A shift in the ligand responsiveness of thyroid hormone receptor alpha induced by heterodimerization with retinoid X receptor alpha. Mol Cell Biol. 1996 Jan; 16(1):219-27. PMID: 8524299; PMCID: PMC230995.
    48. Cavigelli M, Dolfi F, Claret FX, Karin M. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J. 1995 Dec 1; 14(23):5957-64. PMID: 8846788.
      View in: PubMed
    49. Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell. 1995 Jun 30; 81(7):1147-57. PMID: 7600582.
      View in: PubMed
    50. Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science. 1995 Apr 14; 268(5208):286-90. PMID: 7716521.
      View in: PubMed
    51. Saatcioglu F, Claret FX, Karin M. Negative transcriptional regulation by nuclear receptors. Semin Cancer Biol. 1994 Oct; 5(5):347-59. PMID: 7849263.
      View in: PubMed
    52. Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M, Feramisco J, Montminy M. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature. 1994 Jul 21; 370(6486):226-9. PMID: 8028671.
      View in: PubMed
    53. Claret FX, Chapel S, Garcés J, Tsai-Pflugfelder M, Bertholet C, Shapiro DJ, Wittek R, Wahli W. Two functional forms of the Xenopus laevis estrogen receptor translated from a single mRNA species. J Biol Chem. 1994 May 13; 269(19):14047-55. PMID: 8188685.
      View in: PubMed
    54. Schild C, Claret FX, Wahli W, Wolffe AP. A nucleosome-dependent static loop potentiates estrogen-regulated transcription from the Xenopus vitellogenin B1 promoter in vitro. EMBO J. 1993 Feb; 12(2):423-33. PMID: 8440235; PMCID: PMC413225.
    55. Corthésy B, Claret FX, Wahli W. Estrogen receptor level determines sex-specific in vitro transcription from the Xenopus vitellogenin promoter. Proc Natl Acad Sci U S A. 1990 Oct; 87(20):7878-82. PMID: 2236004.
      View in: PubMed
    56. Corthésy B, Cardinaux JR, Claret FX, Wahli W. A nuclear factor I-like activity and a liver-specific repressor govern estrogen-regulated in vitro transcription from the Xenopus laevis vitellogenin B1 promoter. Mol Cell Biol. 1989 Dec; 9(12):5548-62. PMID: 2586526; PMCID: PMC363725.
    57. ten Heggler-Bordier B, Claret FX, Wahli W. Immuno-electron microscopic identification of human estrogen receptor-DNA complexes at the estrogen-responsive element and in the first intron of a Xenopus vitellogenin gene. J Mol Biol. 1988 Nov 5; 204(1):217-20. PMID: 3216393.
      View in: PubMed
    58. Trastuzumab. Frontiers in Oncology. 2 JUN.
    59. Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. Proceedings of the National Academy of Sciences of the United States of America. 110:1273-1278.
    60. Synthesis of (1RS,2RS,5SR)-3,4,6,7-tetramethylidene-8-oxobicyclo[3.2.1]-oct-2-yl acetate and the chemo- and stereoselective coordination of its butadiene functions with rhodium and iron moieties. Organometallics. 9:2785-2792.
    61. RBM24 suppresses cancer progression by upregulating MIR-25 to target MALAT1 in nasopharyngeal carcinoma. Cell Death and Disease. 7.
    62. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma. Leukemia. 29:2162-2172.
    63. Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load. Proteomics - Clinical Applications.
    CLARET's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description